Business
Substantial contract for Proteome Sciences
Proteome Sciences plc has secured a significant new contract with a US biopharmaceutical company for mass spectrometry services to develop a GCLP-compliant assay for an upcoming clinical trial program slated to begin at the end of Q1 2026. A portion of this work is expected to be completed within the current financial year, with the remainder by the end of Q1 2026, mirroring the scope of previous contracts. The company anticipates further contract opportunities from this client and others in the US and Europe for 2026 and 2027. Disclaimer*
About this update from Proteome Sciences Plc
[{"type":"text","content":"\n\n\n \n \nPrior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulations. With the publication of this announcement, this information is now considered to be in the public domain.\n8 December 2025\nProteome Sciences plc\n(\"Proteome Sciences\" or the \"Company\")\n \nSubstantial contract for Proteome Sciences\nProteome Sciences (AIM:PRM), is pleased to announce that the Company has secured a third contract from a US biopharmaceutical company using the Company's mass spectrometry services to develop a new assay at the company's facilities in Frankfurt, Germany in anticipation of starting a new clinical trial programme next year. \nThe initial contract will be designed to comply with Good Clinical Laboratory Practice (\"GCLP\") accreditation and when completed, the new assay will be used to analyse samples from a forthcoming clinical trial due to start at the end of Q1 2026. The next phases of work are anticipated to be similar to the contracts announced in February 2025. A proportion of the work should be completed in the current financial year, with the remainder by the end of Q1 2026.\nCommenting on the contract, Richard Dennis, Chief Commercial Officer of Proteome Sciences said:\n\"We expected to receive additional contracts from the same customer and the targeted assay that we develop is designed to perform under GCLP compliance to monitor drug performance in the new clinical trial planned for early 2026. As in 2024, we continue to see increasing interest for GCLP contracts from other major biopharma clients both in the US and Europe and we hope to secure additional orders in 2026 and 2027.\"\n- Ends -\nFor further information:\n\n\n\n\n\n\n\n\n \nProteome Sciences plc\n\n\n\n\nDr. Ian Pike, Chief Scientific Officer\n\n\nTel: +44 (0)20 7043 2116\n\n\n\n\nRichard Dennis, Chief Commercial Officer\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSP Angel Corporate Finance LLP (Nominated Adviser & Broker) \n\n\n\n\nDavid Hignell/Richard Morrisom/Josh Ray (Corporate Finance)\nVadim Alexandre (Corporate Broking)\n \n \n\n\nTel: +44 (0) 20 3470 0470\n\n\n\n\n \n\n\n\n\n\n\n\n\n\nAbout Proteome Sciences plc. (www.proteomics.com)\n \nP...